----
Current ValuationThe current P/E ratio is 52.05, below the reasonable range, cheaper than 96.55% of the time in the past 1 years, and the industry ranks 56/605, the industry Median -1.88.
52.05xP/E
$417.33Stock price
$8.02Earnings per share
52.05xP/E
Stock price$417.33Earnings per share$8.02
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 70.60x
- Typical range
- 62.28x–532.85x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
014284256
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
ABBVUSAbbvie | 50.32x | 228.97% | $518.44B |
ONCUSBeigene | 52.05x | 255.10% | $47.66B |
GMABUSGenmab A/S | 47.07x | 19.18% | $34.31B |
ZYMEUSZymeworks | 50.48x | 201.77% | $2.19B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
